SCHEMBL7910566

SCHEMBL7910566

COC(=O)C1CCCCN1C(=O)CCCCC1CCSS1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.51
▸ HSD17B10 Q99714 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ TARDBP Q13148 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ NR1I2 O75469 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ APEX1 P27695 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ SAE1 Q9UBE0 1/20 0.48
▸ UBA2 Q9UBT2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7912695 0.97 SIGMAR1 (0.49) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL7919690 0.86 HSD17B10 (0.56) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL12227665 0.84 SIGMAR1 (0.53) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL7915892 0.82 HSD17B10 (0.57) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL10067900 0.82 HSD17B10 (0.57) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL12227662 0.80 HSD17B10 (0.51) SIGMAR1HSD17B10KMT2ATARDBPLMNA
SCHEMBL6882664 0.80 LMNA (0.54) LMNAALDH1A1POLBRAB9ASMN1; SMN2
SCHEMBL5491765 0.80 LMNA (0.54) LMNAALDH1A1POLBRAB9ASMN1; SMN2
SCHEMBL5491755 0.80 LMNA (0.54) LMNAALDH1A1POLBRAB9ASMN1; SMN2
SCHEMBL10036510 0.78 SIGMAR1 (0.52) SIGMAR1HSD17B10KMT2ATARDBPLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257130-A1 Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders CARMEL BIOSCIENCES, INC. 2011-10-20 — — US disclosed
WO-2010045575-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS INVASC THERAPEUTICS, INC. (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257130-A1 Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders REN, ACE, AGT SIGMAR1 4676/4885HSD17B10 292/4885KMT2A 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback